FibroGen (FGEN) $28.5M Shareholder Settlement
FibroGen (FGEN) agreed to settle $28 million with investors to end claims over hiding information about its anemia treatment candidate Roxadustat.
Case Details:
FibroGen and its leaders were accused of not revealing important details about the Roxadustat Phase 3 program.
They supposedly provided false information about the drug's safety.
Moreover, FibroGen's analyses suggested higher risks and doubts about Roxadustat's FDA approval emerged.
On this news, $FGEN dropped when the truth came out.
FibroGen has now decided to resolve all the allegations and pay a $28.5M settlement.
Frequently Asked Questions
All persons who purchased or acquired FibroGen, Inc. securities, including options, between December 20, 2018 through July 15, 2021, inclusive.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
11thestate is an investor recovery company, we help investors to track and collect securities class action settlements. We will:
Prepare documents for your payout
Audit the claim and make sure you get the maximum possible payout
File a claim with the settlement administration
Correspond with the settlement administration to resolve emerging issues
Deliver payout directly to your brokerage account
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.